Core Viewpoint - SciSparc Ltd. has announced an advancement in its collaboration with NeuroThera Labs Inc. by filing a patent application for a novel combination therapy targeting depression, which involves 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] Group 1: Collaboration and Patent Filing - The patent application is a result of the ongoing collaboration between Neurothera and Clearmind Medicine Inc., focusing on a therapy for depression using MEAI and PEA [2][3] - This new filing expands the joint intellectual property portfolio, with a total of 13 patents filed through the collaboration, addressing various conditions including alcohol use disorder, cocaine addiction, obesity, and depression [3] Group 2: Market Context and Impact - According to the World Health Organization, approximately 332 million people globally suffer from major depressive disorder, representing about 5.7% of adults, with higher prevalence in women (6.9%) compared to men (4.6%) [2] - Depression remains one of the leading causes of disability worldwide, significantly contributing to the global burden of disease [2] Group 3: Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments through its majority-owned subsidiary Neurothera Labs Inc., which is engaged in developing cannabinoid-based therapeutics [4] - The company is involved in various drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [4][5]

Core Insights - Clearmind Medicine Inc. has initiated its FDA-approved Phase I/IIa clinical trial for CMND-100 at Hadassah Medical Center, expanding the trial's reach and emphasizing the potential of this non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD) [1][2] Group 1: Clinical Trial Details - The multinational study aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - Hadassah Medical Center was added as a clinical site for the ongoing trial, which was activated swiftly following final approval earlier in the month [2] Group 2: Early Findings - Top-line data from the first cohort of the clinical trial indicated a favorable safety profile, with no serious adverse events reported and high adherence to the dosing regimen [3] - These early findings support the ongoing evaluation of CMND-100 as a potential breakthrough therapy for AUD, a condition affecting millions globally [3] Group 3: Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company's intellectual portfolio includes nineteen patent families with 31 granted patents, and it plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has initiated its FDA-approved Phase I/IIa clinical trial for CMND-100 at Hadassah Medical Center, expanding the trial's reach and emphasizing the potential of this non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD) [1][2] Group 1: Clinical Trial Details - The multinational study aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - Hadassah Medical Center was added as a clinical site following final approval earlier in November 2025, indicating swift activation and commitment to the trial [2] Group 2: Early Findings - Top-line data from the first cohort of the clinical trial showed a favorable safety profile with no serious adverse events reported, indicating that the treatment was well-tolerated among participants [3] - High adherence to the dosing regimen and protocol requirements was observed, supporting the feasibility and patient acceptability of CMND-100 in a clinical setting [3] Group 3: Company Overview - Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics to address widespread health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [5]

Core Insights - Neurothera Labs Inc. announced that Clearmind Medicine Inc. has filed an Israeli patent application for a combination therapy targeting depression, utilizing 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] - The collaboration between Neurothera and Clearmind aims to address the significant global issue of major depressive disorder, which affects over 280 million people and is a leading cause of disability [2] Company Overview - Neurothera Labs Inc. is a clinical-stage biotech company focused on developing innovative therapeutics for central nervous system disorders and other underserved health conditions through collaborations [4] Intellectual Property Development - The recent patent application expands the joint intellectual property portfolio, which now includes 13 patents related to MEAI and N-Acylethanolamines for various conditions, including depression, alcohol use disorder, cocaine addiction, and obesity [3]

Core Insights - Clearmind Medicine Inc. announced positive top-line results from its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][2] - The trial demonstrated a favorable safety profile with no serious adverse events and high treatment adherence among participants, indicating the potential for CMND-100 as a breakthrough therapy for AUD [2][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [5] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] Clinical Trial Details - The first cohort of the trial included six patients, treated at prestigious institutions such as Johns Hopkins University and Yale University, under an FDA-approved protocol [3] - The trial is designed to assess the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in individuals with heavy binge drinking or AUD [3] Executive Commentary - The CEO of Clearmind expressed enthusiasm regarding the initial results, highlighting the encouraging safety profile and treatment observance, which support the company's goal of pioneering therapies for addiction [4]

Core Insights - Clearmind Medicine Inc. has filed a patent application in Israel for a combination therapy targeting depression, utilizing 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] - The collaboration with Neurothera Labs Inc. aims to address the significant global issue of major depressive disorder, which affects over 280 million people and is a leading cause of disability [2] - The CEO of Clearmind emphasized the importance of this patent application as a milestone in developing innovative treatments for mental health conditions, highlighting the lag in treatment innovation for depression [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, including alcohol use disorder [4] - The company has an extensive intellectual property portfolio, currently consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [5] Research and Development - The new patent filing expands Clearmind's intellectual property related to MEAI and N-Acylethanolamines, targeting various conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3] - Preclinical data supports the efficacy of MEAI in reducing addictive behaviors while maintaining normal reward pathways [3]

Core Viewpoint - Clearmind Medicine Inc. has received final approval for its Phase 1/2a clinical trial of CMND-100, a drug candidate for treating Alcohol Use Disorder (AUD), from Hadassah Medical Center in Israel, marking a significant step in addressing AUD, which is responsible for 4.7% of global deaths [1][3]. Group 1: Clinical Trial Details - The clinical trial will involve prestigious institutions such as Yale School of Medicine, Johns Hopkins University, and Tel Aviv Sourasky Medical Center, with leadership from Prof. Joseph Caraco at Hadassah [2]. - The trial aims to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption among AUD patients [3]. Group 2: Company Overview - Clearmind is focused on developing novel psychedelic-derived therapeutics to address significant health issues, including AUD, with the goal of commercializing these compounds as regulated medicines, foods, or supplements [4]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].

Core Insights - Clearmind Medicine Inc. has received notice of publication from the China National Intellectual Property Administration for its proprietary non-hallucinogenic compound, 5-methoxy-2-aminoindane (MEAI), aimed at treating depression [1] - Major depressive disorder affects over 280 million people globally and is a leading cause of disability, with limited innovative treatment options available [2] - Preclinical studies indicate that MEAI may enhance mood regulation and reduce anhedonia, providing a differentiated therapeutic approach for patients unresponsive to conventional antidepressants [3] - Clearmind's intellectual property portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property [4] Company Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address widespread health issues, including alcohol use disorder [4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] - Clearmind's shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0" [5]

Core Insights - Clearmind Medicine Inc. has completed the treatment of the first patient cohort in its Phase I/IIa clinical trial for CMND-100, targeting Alcohol Use Disorder (AUD) [1][5] - The global alcohol-dependency treatment market is projected to grow from approximately $13.2 billion in 2024 to about $20 billion by 2032, indicating a significant unmet need for effective treatments [4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, including AUD [6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [7] Clinical Trial Details - The Phase I/IIa trial is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption [3] - The trial includes participants from leading research centers, with six patients successfully enrolled and treated, including two from Johns Hopkins University and four from Yale School of Medicine [2][3]

Core Points - Clearmind Medicine Inc. received a Notification Letter from Nasdaq indicating non-compliance with Listing Rule 5550(b)(1) due to insufficient stockholders' equity [1][2] - The company's stockholders' equity was reported at $1,065,668, below the required minimum of $2,500,000 [2] - The Notification Letter does not immediately affect the company's listing status, and shares continue to trade under the symbol "CMND" [3] Compliance Plan - Clearmind has 45 days to submit a plan to regain compliance, with a deadline of December 18, 2025 [3] - If the plan is accepted, Nasdaq may grant an extension of up to 180 days to demonstrate compliance [3] - The company is exploring various options to regain compliance and intends to submit the plan as soon as possible [4] Financial Strategies - The company entered into securities purchase agreements to issue convertible promissory notes totaling up to $10,000,000 [5] - As of late October 2025, $1,045,062 of these notes were converted into 885,000 common shares [5] - The company expects that further conversions of the notes will help meet Nasdaq's stockholders' equity requirement [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics for under-treated health issues [6] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [7]